Medvet Science Pty Ltd has licenced XL-99, a cell line of ACYTE Biotech Pty Ltd, for the clinical development of Medvet’s monoclonal antibody (APOMAB®), intended for the diagnosis and treatment of cancers. The target of APOMAB is La/SSB, an essential ribonucleoprotein component found in all cancers, providing the potential for broad oncology applications.
The production of APOMAB in the large quantities potentially required for clinical applications requires a stable cell line with high productivity, robust cell culture processes and a regulatory compliant history.
ACYTE’s XL-99 Chinese hamster ovary (CHO) cell line fulfils these requirements as a high producing line widely used in innovative antibody engineering approaches to produce antibody variants, fusion proteins, and bispecific antibodies. XL-99 is a fully characterised, cGMP banked, CHO-K1 parental cell line with superior growth characteristics which can produce mAbs at high yields and achieve cultures of high cell density.
Prof Michael Brown, who heads the Cancer Clinical Trials Unit at the Royal Adelaide Hospital and who leads ABOMAB clinical development, has commented:
“for clinical efficacy studies of APOMAB, and potential commercial production, we require a cell line capable of producing clinically viable amounts of the antibody, with high cell density at low cost of goods. Our ongoing work with ACYTE indicates that XL-99 will achieve these aims and provide a productive cell line which can be easily transferred to our CMOs”.
Chair of ACYTE, Prof Peter Gray also commented:
“The APOMAB monoclonal antibody is an exciting development which could be useful for the early evaluation of a patient’s response to chemotherapy, bringing significant economic outcomes and improved patient treatment. ACYTE is very pleased to be working with Medvet using XL-99 as a production platform for the clinical development of this innovative antibody to detect and treat cancer”.
The commercial terms of the licence have not been disclosed, the arrangements provide access to the XL-99 cell line to manufacture and conduct clinical development of the APOMAB antibody. Medvet are currently undertaking clinical proof-of-concept development of APOMAB at the Royal Adelaide Hospital, under the supervision of Prof Michael Brown and there are further plans to develop antibody–drug conjugates (ADC) for treatment of lung cancer. ACYTE continues to work with Medvet and a range of biotech companies generating stable, high-producing cell lines for recombinant protein production.
About Medvet Sciences: Medvet is a private company whose sole shareholder is Central Adelaide Local Health Network (CALHN) - a division of SA Health, South Australia's government department responsible for maintaining and managing the health of all South Australians. The company is a national provider of on-site health and safety services delivered by qualified and experienced professional staff to businesses all over Australia.
About ACYTE Biotech: ACYTE specialises in supplying its proprietary mammalian cell lines and technologies to enhance cell engineering and culture processes to streamline biologics development from discovery to clinic. ACYTE provides biotech companies adaptable, stable and robust cell lines with superior growth performance for expression of monoclonal antibodies, fusion proteins, antibody fragments, recombinant proteins, etc. ACYTE’s suite of SuperCHO® technologies span stable and transient cell lines, antibody vectors and clonal isolation processes.
Contact: Dr Aoife Cullen, [email protected], +61-417-644-056
ACYTE Biotech is an Australian based company specializing in proprietary technologies in mammalian cell engineering and cell culture. We supply proprietary mammalian cell lines and technologies to enhance cell engineering and culture processes to streamline biologics development from discovery to clinic. ACYTE provides companies adaptable, stable and robust cell lines with superior growth performance for expression of monoclonal antibodies, fusion proteins, antibody fragments, recombinant proteins, etc.
ACYTE’s suite of SuperCHO® technologies span stable and transient cell lines, antibody vectors and clonal isolation processes.